Toraih Eman A, Hussein Mohammad H, Zerfaoui Mourad, Attia Abdallah S, Marzouk Ellythy Assem, Mostafa Arwa, Ruiz Emmanuelle M L, Shama Mohamed Ahmed, Russell Jonathon O, Randolph Gregory W, Kandil Emad
Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Genetics Unit, Department of Histology and Cell Biology, Suez Canal University, Ismailia 41522, Egypt.
Cancers (Basel). 2021 Apr 1;13(7):1625. doi: 10.3390/cancers13071625.
Introduction-heterogeneity in clinical outcomes and survival was observed in patients with papillary thyroid cancer (PTC) and distant metastases. Here, we investigated the effect of distant metastases sites on survival in PTC patients. Methods-patients with a diagnosis of PTC and known metastases were identified using the Surveillance, Epidemiology, and End Results database (1975-2016). Univariate and multivariate Cox regression analyses were performed to analyze the effect of distant metastases sites on thyroid cancer-specific survival (TCSS) and overall survival (OS). Results-from 89,694 PTC patients, 1819 (2%) developed distant metastasis at the initial diagnosis, of whom 26.3% presented with the multiple-organ disease. The most common metastatic sites were lung (53.4%), followed by bone (28.1%), liver (8.3%), and brain (4.7%). In metastatic patients, thyroid cancer-specific death accounted for 73.2%. Kaplan-Meier curves showed decreased OS in patients with metastases to the brain (median OS = 5 months) and liver (median OS = 6 months) compared to lung (median OS = 10 months) and bone (median OS = 23 months). Moreover, multiple organ metastasis had a higher mortality rate (67.4%) compared to single organ metastasis (51.2%, < 0.001). Using multivariate analysis, risk factors that significantly influence TCSS and OS were male gender (HR = 1.86, 95% CI = 1.17-2.94, < 0.001, and HR = 1.90, 95% CI = 1.40-2.57, 0.009), higher tumor grade (HR = 7.31, 95% CI = 2.13-25.0, < 0.001 and HR = 4.76, 95% CI = 3.93-5.76, < 0.001), multiple organ involvement (HR = 6.52, 95% CI = 1.50-28.39, = 0.026 and HR = 5.08, 95% CI = 1.21-21.30, = 0.013), and brain metastasis (HR = 1.82, 95% CI = 1.15-2.89, < 0.001 and HR = 4.21, 95% CI = 2.20-8.07, = 0.010). Conclusion-the pattern of distant metastatic organ involvement was associated with variability in OS in PTC. Multi-organ metastasis and brain involvement are associated with lower survival rates in PTC. Knowledge of the patterns of distant metastasis is crucial to personalize the treatment and follow-up strategies.
引言——在甲状腺乳头状癌(PTC)伴远处转移的患者中观察到临床结局和生存存在异质性。在此,我们研究了远处转移部位对PTC患者生存的影响。方法——利用监测、流行病学和最终结果数据库(1975 - 2016年)识别诊断为PTC且有已知转移的患者。进行单因素和多因素Cox回归分析,以分析远处转移部位对甲状腺癌特异性生存(TCSS)和总生存(OS)的影响。结果——在89694例PTC患者中,1819例(2%)在初次诊断时发生远处转移,其中26.3%为多器官疾病。最常见的转移部位是肺(53.4%),其次是骨(28.1%)、肝(8.3%)和脑(4.7%)。在转移患者中,甲状腺癌特异性死亡占73.2%。Kaplan - Meier曲线显示,与肺转移(中位OS = 10个月)和骨转移(中位OS = 23个月)相比,脑转移(中位OS = 5个月)和肝转移(中位OS = 6个月)患者的OS降低。此外,多器官转移的死亡率(67.4%)高于单器官转移(51.2%,P < 0.001)。多因素分析显示,显著影响TCSS和OS的危险因素包括男性(HR = 1.86,95%CI = 1.17 - 2.94,P < 0.001;HR = 1.90,95%CI = 1.40 - 2.57,P = 0.009)、较高的肿瘤分级(HR = 7.31,95%CI = 2.13 - 25.0,P < 0.001;HR = 4.76,95%CI = 3.93 - 5.76,P < 0.001)、多器官受累(HR = 6.52,95%CI = 1.50 - 28.39,P = 0.026;HR = 5.08,95%CI = 1.21 - 21.30,P = 0.013)和脑转移(HR = 1.82, 95%CI = 1.15 - 2.89, P < 0.001;HR = 4.21, 95%CI = 2.20 - 8.07, P = 0.010)。结论——远处转移器官受累模式与PTC患者的OS变异性相关。多器官转移和脑受累与PTC患者较低的生存率相关。了解远处转移模式对于个性化治疗和随访策略至关重要。